ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 849

Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database

Raphaèle Seror1, Alexandre Lafourcade 2, yann De Rycke 2, Bruno Fautrel 3, Xavier Mariette 4 and Florence Tubach 5, 1Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, 2Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, 3Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologics, Disease-modifying antirheumatic drugs, malignancy and lymphoma, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: 3S080: RA – Treatments I: Safety and Outcomes (845–850)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.

Methods: We conducted an historical cohort study within our national claim database that prospectively records individual health resource use of 86% of the French population (65 million inhabitants). RA adult patients were identified based on ICD-10 code (M05 or M06) between 2007-2016. Patients with previouscancer history were excluded.

Treatment exposures were incident first use of any treatment: csDMARD (methotrexate, leflunomide, sulfasalazine, azathioprine, hydroxychloroquine) or biologics (anti-TNF, rituximab, abatacept, tocilizumab, ustekinumab, anakinra). To identify incident treatment periods, a one year period prior our period of analysis was analysed; only patients that did not receive any treatment during this period were included. .Exposure definition was considered with a 90-day latency after treatment initiation and a 180-day remanence period after drug discontinuation.

To compare the risk of malignancies between csDMARD and biologics treated patients, a dynamically propensity score (including age, sexe, year of first occurrence of RA code, date of treatment initiation, number of previous DMARDs, Charlson comorbidity index, diagnosis of tobacco and/or alcohol-associated disorders, number of hospitalisations for RA, cumulative corticosteroid dose ) was constructed using pooled logistic regression. Hazard Ratios (HRs) for risk of cancer were estimated using Cox proportional hazards model after dynamically propensity score matching. Exposure was considered as a time-dependent variable. Sensitivity analyses are ongoing to assess the robustness of our results.

Results: Between 2007 and 2016, 83 706 RA patients exposed to csDMARD (n=63837) and/or biologics (n=19869) were identified. After propensity score matching, analyses were conducted on 19687 patients in each group (mean age: 51 ±14 yrs; female: 74.6%). Malignancies occurred in 435 patients exposed to biologics and 357 patients exposed to csDMARD,

The HR for overall risk of malignancies, risk of solid cancer (excluding non-melanoma skin cancer), lymphoma, and other hematologic malignancies did not differ significantly between csDMARD and all biologics analysed together (table). Regarding organ specific cancer, no difference was observed, except for risk of prostate cancer in men that occurred significantly less frequently in biologic treated patients (HR: 0.47 [0.29;0.76], p=0.003).

Conclusion: Using a large nationwide healthcare database, representative of the French population, the overall risk of malignancies and the risk of organ-specific cancers and hematologic malignancies in biologic treated RA patients did not differ from that of patients treated with csDMARD. Except for prostate cancer in men, which occurred less  frequently in biologics treated patients. The reason of this difference remains unclear, but could be linked to a high frequency of screening before introducing biologic.

Risk of cancer of biologics compared to csDMARD in RA patients


Disclosure: R. Seror, bms, 5, BMS, 5, GSK, 5, gsk, 5, pfizer, 5, PFIZER, 5, ROCHE, 5, roche, 5; A. Lafourcade, None; y. De Rycke, None; B. Fautrel, AbbVie, 2, 5, 8, Biogen, 5, 8, BMS, 5, 8, Boehringer Ingelheim, 8, Celgene, 5, 8, Eli Lilly and Company, 2, 5, Janssen, 5, 8, Lilly, 8, Medac, 5, 8, MSD, 2, 5, 8, NORDIC Pharma, 5, 8, Novartis, 5, 8, Pfizer, 2, 5, 8, Roche, 5, 8, Sanofi-Aventis, 5, SOBI, 5, 8, UCB, 5, 8; X. Mariette, Biogen, 2, Bristol-Myers Squibb, 5, GlaxoSmithKline, 5, Janssen, 5, LFB Pharmaceuticals, 5, OSE Immunotherapeutics, 2, Pfizer, 2, 5, UCB Pharma, 5, 8; F. Tubach, MSD, 5.

To cite this abstract in AMA style:

Seror R, Lafourcade A, De Rycke y, Fautrel B, Mariette X, Tubach F. Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/risk-of-malignancies-associated-with-biologics-in-rheumatoid-arthritis-analysis-of-a-national-claim-database/. Accessed July 1, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-malignancies-associated-with-biologics-in-rheumatoid-arthritis-analysis-of-a-national-claim-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies